As the key downstream stage from candidate sequences to scaled sample preparation, the platform provides seven service categories: recombinant antibodies, chimeric antibodies, antibody fragments, bispecific antibodies, modified antibodies, anti-idiotypic antibodies, and ADC conjugation process development. Built on two mammalian expression systems, HEK293 and CHO, it supports stable lot-to-lot performance and covers project needs from research-grade pilot samples through scaled-up production.
Our in-house-optimized mammalian platform delivers high-efficiency, high-level recombinant antibody expression in HEK293 and CHO cells. Beyond full-length antibodies, it supports Fab, scFv, sdAb/VHH, Fc-fusion proteins, chimeric antibodies, bispecific antibodies and other formats.
Our recombinant antibody expression specialists bring more than fifteen years of project experience, producing high-quality antibodies for IVD raw materials, early drug discovery and preclinical research.
Antibody production is carried out on protein expression platforms: HEK293 and CHO mammalian systems are suited to full-length antibodies and complex molecular formats, the E. coli system supports rapid production of antibody fragments, and stable cell lines support long-term scaled supply.
Mammalian expression platformCHO/HEK293 hosts with full folding and post-translational modification give proteins that closely match the native state in structure, physicochemistry and function.
Learn more
E. coli expression platformA streamlined prokaryotic system combining short timelines, controlled cost and high yield, supporting rapid scale-up of the target protein.
Learn more
Stable cell line platformHigh-expressing, highly stable monoclonal lines are screened for long-term, large-scale production, safeguarding process stability and batch consistency.
Learn more
Mesothelin, long underestimated, has moved from the lab to the clinical frontier across CAR-T, ADCs and bispecifics. With our cellular EC50 and internalisation data.
May 27, 2026
Both formats drop parts of the native immunoglobulin. We compare structure, solubility, stability, size and production cost, then their therapeutic use.
Jul 15, 2026
Heavy-chain-only antibodies, found in camelids and cartilaginous fish in the 1990s, lose the CH1 domain and pair no light chain — leaving a single variable domain of roughly 15 kDa, nanometre-scale.
Jun 10, 2026
Once the sequence is confirmed, expression, purification and QC all run to one quality standard; whether it's a research-grade sample or scaled supply, every batch ships with a full CoA and raw data.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
